Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
2019 1
2020 3
2022 4
2023 2
2024 1

Text availability

Article attribute

Article type

Publication date

Search Results

10 results

Results by year

Filters applied: . Clear all
Page 1
A Phase II Study of FOLFIRI Plus Ziv-Aflibercept After Trifluridine/Tipiracil Plus Bevacizumab in Patients with Metastatic Colorectal Cancer: WJOG 11018G.
Matsumoto T, Yamamoto Y, Kotaka M, Masuishi T, Tsuji Y, Shoji H, Hirata K, Tsuduki T, Makiyama A, Izawa N, Takahashi N, Tsuda M, Yasui H, Ohta T, Kito Y, Otsu S, Hironaka S, Yamazaki K, Boku N, Hyodo I, Yoshimura K, Muro K. Matsumoto T, et al. Among authors: tsuduki t. Target Oncol. 2024 Mar;19(2):181-190. doi: 10.1007/s11523-024-01043-2. Epub 2024 Mar 1. Target Oncol. 2024. PMID: 38427280 Free PMC article. Clinical Trial.
Takotsubo cardiomyopathy caused by infusion reaction to trastuzumab.
Matsumoto T, Oda T, Yoshida Y, Kimura S, Himei H, Tsuduki T, Takagi S, Takatani M, Morishita H. Matsumoto T, et al. Among authors: tsuduki t. Int Cancer Conf J. 2019 Dec 6;9(1):28-31. doi: 10.1007/s13691-019-00396-0. eCollection 2020 Jan. Int Cancer Conf J. 2019. PMID: 31950014 Free PMC article.
Real-World Data of Trifluridine/Tipiracil for Patients With Advanced Gastric Cancer: A Multi-Institutional Retrospective Study.
Matsumoto T, Yamamura S, Ikoma T, Kurioka Y, Doi K, Yasuda T, Boku S, Kawai T, Shibata N, Nagai H, Tsuduki T, Shimada T, Matsumoto Y, Tsumura T, Takatani M, Yasui H, Satake H. Matsumoto T, et al. Among authors: tsuduki t. Clin Med Insights Oncol. 2022 Nov 14;16:11795549221137135. doi: 10.1177/11795549221137135. eCollection 2022. Clin Med Insights Oncol. 2022. PMID: 36408335 Free PMC article.
Risk factors and efficacy outcomes of early-onset severe neutropenia due to paclitaxel or nanoparticle albumin-bound paclitaxel combined with ramucirumab in advanced gastric cancer: a multicenter retrospective cohort study.
Hagiwara Y, Nakasya A, Matsumoto T, Ikoma T, Yamamoto Y, Kurioka Y, Tsuduki T, Kajiwara T, Nishina T, Yamashita N, Moriwaki T, Hyodo I. Hagiwara Y, et al. Among authors: tsuduki t. J Gastrointest Oncol. 2022 Dec;13(6):2769-2778. doi: 10.21037/jgo-22-499. J Gastrointest Oncol. 2022. PMID: 36636083 Free PMC article.
Nanoparticle albumin-bound paclitaxel and ramucirumab versus paclitaxel and ramucirumab as second-line chemotherapy for unresectable advanced or recurrent gastric cancer: a multicenter, propensity score-matched analysis (CROSS SELL study).
Nakasya A, Hagiwara Y, Ikoma T, Kurioka Y, Matsumoto T, Yamamoto Y, Tsuduki T, Kajiwara T, Moriwaki T, Nishina T, Yamashita N, Hyodo I. Nakasya A, et al. Among authors: tsuduki t. Int J Clin Oncol. 2022 Apr;27(4):684-694. doi: 10.1007/s10147-022-02114-y. Epub 2022 Jan 28. Int J Clin Oncol. 2022. PMID: 35089459 Free PMC article.